3651 results for «211»
3651 results
Left main interventions: pushing the boundaries
21 May 2026 – From EuroPCR 2026
Examine contemporary strategies for distal left main bifurcation disease treatment, including debates on complex bifurcation and high-risk PCI approaches. The session emphasizes the critical role of coronary imaging in guiding decision-making and showcases clinical cases illustrating management of left main interventions under challenging conditions.
Technical decision-making for CTO PCI strategy
22 May 2026 – From EuroPCR 2026
This session focuses on technical decision-making for chronic total occlusion PCI strategy. It presents diverse approaches to right coronary CTOs, complex management involving double rendezvous techniques, subintimal strategies, and innovative single-injection methods, demonstrating the evolving frontiers in CTO intervention.
Unusual clinical cases: thinking beyond the routine
22 May 2026 – From EuroPCR 2026
This session presents unusual and challenging clinical cases that extend beyond routine interventional cardiology. From optimised in-stent restenosis treatment to rare anatomical anomalies and complex thrombus management, it offers valuable lessons in creative problem-solving and advanced intervention techniques.
Atypical NSTEMI culprit lesions
22 May 2026 – From EuroPCR 2026
Focusing on atypical NSTEMI culprit lesions, this session examines rare presentations such as calcific emboli, coronary anomalies, and unusual routes to revascularisation. It provides clinical insights into diagnosing and managing uncommon acute coronary syndromes effectively.
Clinical decision making for CTO PCI strategy
22 May 2026 – From EuroPCR 2026
This session explores clinical decision-making in CTO PCI strategy through complex scenarios including multivessel CTO in ischemic cardiomyopathy, high-risk NSTEMI post-vein graft failure, and challenges in elderly patients. It emphasizes strategic planning and individualized approaches to optimize outcomes.
Overcoming challenging anatomy in calcified lesion PCI
22 May 2026 – From EuroPCR 2026
This session focuses on overcoming the challenges posed by complex anatomical variations in calcified lesion PCI. Experts present advanced techniques and hybrid solutions for difficult bifurcation angles, aorto-ostial lesions, and other complex scenarios, emphasizing both innovative and simplified approaches to achieve procedural success.
Spontaneous coronary artery dissection management with intracoronary imaging
22 May 2026 – From EuroPCR 2026
Explore the nuanced management of spontaneous coronary artery dissection (SCAD) with a focus on intracoronary imaging. This session examines diagnostic challenges, the limited role of coronary CT angiography, and strategies for managing occlusive SCAD cases, highlighting the evolving understanding of this complex condition.
Diversity in coronary artery disease treatment
22 May 2026 – From EuroPCR 2026
Focusing on the diversity in coronary artery disease treatment, this session highlights challenges ranging from maintaining interventional cardiology services during conflict to the influence of comorbidities such as type 2 diabetes mellitus on prognosis and risk assessment. It also presents clinical outcomes related to stent thrombosis...
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024